Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/medicina57030199 http://scihub22266oqcxt.onion/10.3390/medicina57030199 33652582!7996517!33652582     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Medicina+(Kaunas) 2021 ; 57 (3): ä Nephropedia Template TP {{tp|p=33652582|t=2021. Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials |pdf=|usr=}}{{33652582}} gab.com Text Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials JO: Medicina (Kaunas) http://www.kidney.de/pget.php?&tw=1&pmid=33652582 #FOAvip Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trials. Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows: relative risk reduction, 95.1%; 95% CI, 90.0% to 97.6%; p = 0.016; absolute risk reduction, 0.7%; 95% CI, 0.59% to 0.83%; p < 0.000. For the Moderna vaccine mRNA-1273, the appraisal shows: relative risk reduction, 94.1%; 95% CI, 89.1% to 96.8%; p = 0.004; absolute risk reduction, 1.1%; 95% CI, 0.97% to 1.32%; p < 0.000. Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures. Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy. Twit Text FOAVip Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials ????Medicina (Kaunas) http://www.kidney.de/pget.php?&tw=1&pmid=33652582 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33652582 #FOAvip English Wikipedia <ref>{{Cite pmid|33652582}}</ref> Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials #MMPMID33652582 Brown RB Medicina (Kaunas) 2021[Feb]; 57 (3): ä PMID33652582show ga Relative risk reduction and absolute risk reduction measures in the evaluation of clinical trial data are poorly understood by health professionals and the public. The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. The present article uses clinical epidemiologic tools to critically appraise reports of efficacy in Pfzier/BioNTech and Moderna COVID-19 mRNA vaccine clinical trials. Based on data reported by the manufacturer for Pfzier/BioNTech vaccine BNT162b2, this critical appraisal shows: relative risk reduction, 95.1%; 95% CI, 90.0% to 97.6%; p = 0.016; absolute risk reduction, 0.7%; 95% CI, 0.59% to 0.83%; p < 0.000. For the Moderna vaccine mRNA-1273, the appraisal shows: relative risk reduction, 94.1%; 95% CI, 89.1% to 96.8%; p = 0.004; absolute risk reduction, 1.1%; 95% CI, 0.97% to 1.32%; p < 0.000. Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures. Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy. |*Bias[MESH] |2019-nCoV Vaccine mRNA-1273[MESH] |BNT162 Vaccine[MESH] |COVID-19 Vaccines/*therapeutic use[MESH] |COVID-19/*prevention & control[MESH] |Clinical Trials as Topic/*statistics & numerical data[MESH] |Humans[MESH] |Numbers Needed To Treat/*statistics & numerical data[MESH] |RNA, Viral/drug effects[MESH] |Risk[MESH] |SARS-CoV-2/drug effects[MESH]Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials (epmc).pdf DeepDyve Pubget Overpricing